JP2011528897A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528897A5
JP2011528897A5 JP2011519187A JP2011519187A JP2011528897A5 JP 2011528897 A5 JP2011528897 A5 JP 2011528897A5 JP 2011519187 A JP2011519187 A JP 2011519187A JP 2011519187 A JP2011519187 A JP 2011519187A JP 2011528897 A5 JP2011528897 A5 JP 2011528897A5
Authority
JP
Japan
Prior art keywords
tuberculosis
prevention
treatment
protein sequence
rv1753c protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011519187A
Other languages
English (en)
Japanese (ja)
Other versions
JP5824360B2 (ja
JP2011528897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/059586 external-priority patent/WO2010010180A1/en
Publication of JP2011528897A publication Critical patent/JP2011528897A/ja
Publication of JP2011528897A5 publication Critical patent/JP2011528897A5/ja
Application granted granted Critical
Publication of JP5824360B2 publication Critical patent/JP5824360B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011519187A 2008-07-25 2009-07-24 新規化合物および方法 Expired - Fee Related JP5824360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8369208P 2008-07-25 2008-07-25
US61/083,692 2008-07-25
PCT/EP2009/059586 WO2010010180A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (3)

Publication Number Publication Date
JP2011528897A JP2011528897A (ja) 2011-12-01
JP2011528897A5 true JP2011528897A5 (enExample) 2012-09-06
JP5824360B2 JP5824360B2 (ja) 2015-11-25

Family

ID=41172233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011519187A Expired - Fee Related JP5824360B2 (ja) 2008-07-25 2009-07-24 新規化合物および方法

Country Status (24)

Country Link
US (2) US9315556B2 (enExample)
EP (1) EP2315597B1 (enExample)
JP (1) JP5824360B2 (enExample)
KR (2) KR20110060891A (enExample)
CN (2) CN108059660A (enExample)
AU (1) AU2009273133B2 (enExample)
BR (1) BRPI0916705A2 (enExample)
CA (1) CA2731549C (enExample)
CO (1) CO6400198A2 (enExample)
CY (1) CY1119737T1 (enExample)
EA (1) EA022203B1 (enExample)
ES (1) ES2647321T3 (enExample)
HR (1) HRP20171694T1 (enExample)
HU (1) HUE037121T2 (enExample)
IL (1) IL210588A0 (enExample)
LT (1) LT2315597T (enExample)
MX (1) MX2011000981A (enExample)
NO (1) NO2315597T3 (enExample)
PL (1) PL2315597T3 (enExample)
PT (1) PT2315597T (enExample)
SG (1) SG10201505149WA (enExample)
SI (1) SI2315597T1 (enExample)
UA (1) UA107180C2 (enExample)
WO (1) WO2010010180A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20181353T1 (hr) 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US20140349320A1 (en) * 2011-12-15 2014-11-27 The Trustees Of The University Of Pennsylvania Using Adaptive Immunity to Detect Drug Resistance
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CA3045952A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
WO2020214961A1 (en) * 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Methods of treating tuberculosis
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016146A (en) * 1974-12-10 1977-04-05 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies, and use
DE69313134T2 (de) * 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
BR9909472A (pt) 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
AU7383500A (en) 1999-09-17 2001-04-17 United States Government, As Represented By The Department Of Veteran's Affairs Virulence genes of m. marinum and m. tuberculosis
EP1229931A4 (en) 1999-10-07 2003-05-28 Corixa Corp FUSION PROTEINS FROM MYCOBACTERIUM TUBERCULOSIS
WO2001062893A2 (en) 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
PT2133100E (pt) 2000-06-20 2012-01-11 Corixa Corp Antigénio mtb32a de mycobacterium tuberculosis com um local activo inactivado e suas proteínas de fusão
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
US7424370B2 (en) * 2004-02-06 2008-09-09 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
EP2315773B1 (en) * 2008-07-25 2016-08-24 GlaxoSmithKline Biologicals S.A. Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
HRP20181353T1 (hr) 2008-07-25 2018-10-19 Glaxosmithkline Biologicals S.A. Tuberkulozni protein rv2386c, njegovi pripravci i upotreba
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
US8367055B2 (en) 2009-05-14 2013-02-05 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
LT2528621T (lt) 2010-01-27 2016-12-12 Glaxosmithkline Biologicals S.A. Modifikuoti tuberkuliozės antigenai

Similar Documents

Publication Publication Date Title
JP2011528896A5 (enExample)
JP2011528895A5 (enExample)
JP2012126742A5 (enExample)
JP2012136541A5 (enExample)
JP2014530220A5 (enExample)
JP2013231081A5 (enExample)
CA2818990C (en) Designed repeat proteins binding to serum albumin
JP2015518818A5 (enExample)
JP2013172734A5 (enExample)
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
JP2015517488A5 (enExample)
JP2015517489A5 (enExample)
JP2009268467A5 (enExample)
JP2013520405A5 (enExample)
JP2011136997A5 (enExample)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
JP2014529399A5 (enExample)
JP2008536483A5 (enExample)
NZ608502A (en) Polypeptides that bind to human complement component c5
JP2011511805A5 (enExample)
JP2012532874A5 (enExample)
JP2013507439A5 (enExample)
JP2008530245A5 (enExample)
JP2011500073A5 (enExample)
JP2013510169A5 (enExample)